Clearmind Medicine Inc.(CMND)Earnings, Financials & Key Ratios
CMND•NASDAQ
$2.38
Price updated Jun 27, 2026
AboutClearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$6M+1.3%
- Net Income-$4M+26.6%
- EPS (Diluted)-3.03+55.3%
- ROE-139.78%+29.4%
CMND Price & Volume
Clearmind Medicine Inc. (CMND) stock price & volume — 10-year historical chart
Loading chart...
Pre-Revenue Biotech Faces Persistent Capital Erosion
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent dilutive financing risk
"Clearmind Medicine operates as a high-risk, pre-revenue entity where valuation is entirely contingent upon future clinical milestones rather than current operational performance. The firm's reliance on external capital to fund its $3.6 million quarterly R&D and SG&A expenditure creates a precarious financial outlook for shareholders. Investors should monitor the company's ability to manage its $33.8 million accumulated deficit while navigating the significant dilution risks inherent in its current cash-burn trajectory."
Verdict Logic
the company's consistent quarterly cash burn and the lack of revenue generation, combined with a $33.8 million accumulated deficit, suggest that further dilutive equity financing is likely required to maintain operations.
CMND Growth Metrics
Clearmind Medicine Inc. (CMND) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-63.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-143.37%
Return on Capital
10 Years-266.19%
5 Years-397.74%
3 Years-353.36%
Last Year-204.53%
CMND Recent Earnings
Clearmind Medicine Inc. (CMND) EPS & revenue vs analyst estimates — last 4 quarters
Q3 2026Latest
Jun 15, 2026Metric
Actual
Est
EPS
$6.78
—
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$3.32
—
Rev
—
—
Q1 2026
Jan 28, 2026Metric
Actual
Est
EPS
$4.40
—
Rev
—
—
Q4 2025
Sep 11, 2025Metric
Actual
Est
EPS
$10.00
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 15, 2026 | $6.78 | — |
| Q2 2026 | Mar 12, 2026 | $3.32 | — |
| Q1 2026 | Jan 28, 2026 | $4.40 | — |
| Q4 2025 | Sep 11, 2025 | $10.00 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Clearmind Medicine Inc. (CMND)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.38 | $2.43M | -0.79 | — | — | -139.78% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $14.82 | $1.42B | -4.81 | — | — | -151.02% | — | |
| $5.29 | $1.95B | -1.82 | 1227.6% | -19019.44% | -366.21% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $138.76 | $19.01B | 6222.42 | 2.72% | 3.46% | 2.79% | — |
Compare CMND vs Peers
Clearmind Medicine Inc. (CMND) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CMND posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CMND Frequently Asked Questions
Clearmind Medicine Inc. (CMND) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CMND profitable?
Clearmind Medicine Inc. (CMND) reported a net loss of $7.9M for fiscal year 2025.
Dividend & Returns
What is CMND's return on equity?
Clearmind Medicine Inc. (CMND) has a return on equity (ROE) of -139.8%. Negative ROE indicates the company is unprofitable.
What is Clearmind Medicine Inc.'s free cash flow?
Clearmind Medicine Inc. (CMND) had negative free cash flow of $6.8M in fiscal year 2025, likely due to heavy capital investments.